Calls for papers
-
MannKind Corporation announced that the FDA has accepted the company’s sBLA for the use of Afrezza inhaled dry powder insulin in diabetes patients aged 4 to 17 and has set a PDUFA date of May 29, 2026.… Read more . . .
-
German CDMO LTS Lohmann has announced that it will acquire US-based CDMO Renaissance Lakewood, which specializes in injectables and nasal sprays. According to the announcement, Renaissance currently employs approximately 500 employees. LTS currently offers services for… Read more . . .
-
Inhalation CDMO Bespak has announced the appointment of former automotive industry executive Tarik Hage as Chief Commercial Officer. Hage was most recently VP of Commercial and Business Development at GKN Automotive, where he had worked… Read more . . .
-
Chance Pharmaceuticals has announced a new agreement giving Huadong Medicine the rights to commercialize Chance Pharma’s CXG87 formoterol / budesonide DPI in mainland China. Financial details of the agreement were not disclosed. In March 2025,… Read more . . .
-
Nasus Pharma announced that it has signed a deal with Aptar for the use of Aptar’s Unit Dose System (UDS) nasal powder delivery device for Nasus’ NS002 (formerly FMXIN002) intranasal dry powder epinephrine product candidate… Read more . . .
-
Lupin has announced that it will invest $250 million over 5 years to build a new 70,000 sq ft inhaler manufacturing facility in Coral Springs, Florida, USA, where the company opened an inhalation research center… Read more . . .
-
According to ARS Pharmaceuticals, both the US Patent and Trademark Office and the European Patent Office have upheld the validity of claims in patents related to neffy epinephrine nasal spray / EURneffy adrenaline nasal spray.… Read more . . .
-
Italian biotech NanoPhoria Bioscience announced that it has raised €83.5 million in Series A financing to support development of its NP-MP1 “lung-to-heart nano-in-micro technology.” The company notes that the €83.5 million funding is the largest… Read more . . .
-
AeroRx Therapeutics announced that it has closed a $21 million Series A financing to support continued development of the company’s AERO-007 indacaterol / glycopyrrolate inhalation solution for the treatment of COPD. In 2022, AeroRx announced… Read more . . .
-
Orexo announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company $8 million to support the development of OX390, a new chemical entity formulated for nasal delivery for the reversal… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland